Immunome/IMNM

$26.00

4.75%
-
1D1W1MYTD1YMAX

About Immunome

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company’s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. Its proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of antibodies and targets. Its lead discovery programs include Oncology (IMM-ONC-01) and SARS-CoV-2 (IMM-BCP-01). Its IMM-ONC-01 is its lead oncology program targets interleukin 38 (IL-38), which is a negative regulator of inflammation capable of promoting tumor evasion of the immune system. The Company is developing an antibody cocktail derived from the B cells of COVID-19 patients who exhibited high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2, which include highly conserved, subdominant epitopes. The IMM-BCP-01 program is focused on the variants of SARS-CoV-2.

Ticker

IMNM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Clay Siegall

Employees

37

Headquarters

Exton, United States

Immunome Metrics

BasicAdvanced
$1.26B
Market cap
-
P/E ratio
-$1.80
EPS
1.66
Beta
-
Dividend rate

What the Analysts think about Immunome

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
28.85% upside
High $40.00
Low $27.00
$26.00
Current price
$33.50
Average price target

Immunome Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-122.85% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.5M
-16.67%
Net income
$-4.3M
-21.82%
Profit margin
-122.85%
-6.19%

Immunome Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 187.5%
QuarterlyAnnual
Q3 22
Q4 22
Q1 23
Q2 23
Q4 23
Actual
-$0.75
-$0.64
-$0.35
-$0.46
-
Expected
-$0.76
-$0.68
$0.59
-$0.16
-$0.28
Surprise
-1.32%
-5.19%
-159.83%
187.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Immunome stock

Buy or sell Immunome stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing